首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): Primary analysis of Radiation Therapy Oncology Group (RTOG) 0515
【24h】

A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): Primary analysis of Radiation Therapy Oncology Group (RTOG) 0515

机译:非小细胞肺癌(NSCLC)剂量规划中有无PET / CT融合的总肿瘤体积定义的II期比较研究:放射治疗肿瘤学组(RTOG)0515的初步分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Radiation Therapy Oncology Group (RTOG) 0515 is a Phase II prospective trial designed to quantify the impact of positron emission tomography (PET)/computed tomography (CT) compared with CT alone on radiation treatment plans (RTPs) and to determine the rate of elective nodal failure for PET/CT-derived volumes. Methods: Each enrolled patient underwent definitive radiation therapy for non-small-cell lung cancer (≥60 Gy) and had two RTP datasets generated: gross tumor volume (GTV) derived with CT alone and with PET/CT. Patients received treatment using the PET/CT-derived plan. The primary end point, the impact of PET/CT fusion on treatment plans was measured by differences of the following variables for each patient: GTV, number of involved nodes, nodal station, mean lung dose (MLD), volume of lung exceeding 20 Gy (V20), and mean esophageal dose (MED). Regional failure rate was a secondary end point. The nonparametric Wilcoxon matched-pairs signed-ranks test was used with Bonferroni adjustment for an overall significance level of 0.05. Results: RTOG 0515 accrued 52 patients, 47 of whom are evaluable. The follow-up time for all patients is 12.9 months (2.7-22.2). Tumor staging was as follows: II = 6%; IIIA = 40%; and IIIB = 54%. The GTV was statistically significantly smaller for PET/CT-derived volumes (98.7 vs. 86.2 mL; p < 0.0001). MLDs for PET/CT plans were slightly lower (19 vs. 17.8 Gy; p = 0.06). There was no significant difference in the number of involved nodes (2.1 vs. 2.4), V20 (32% vs. 30.8%), or MED (28.7 vs. 27.1 Gy). Nodal contours were altered by PET/CT for 51% of patients. One patient (2%) has developed an elective nodal failure. Conclusions: PET/CT-derived tumor volumes were smaller than those derived by CT alone. PET/CT changed nodal GTV contours in 51% of patients. The elective nodal failure rate for GTVs derived by PET/CT is quite low, supporting the RTOG standard of limiting the target volume to the primary tumor and involved nodes.
机译:背景:放射治疗肿瘤学组(RTOG)0515是一项II期前瞻性试验,旨在量化与单独使用CT相比,正电子发射断层扫描(PET)/计算机断层扫描(CT)对放射治疗计划(RTP)的影响并确定发生率PET / CT衍生体积的选择性淋巴结衰竭。方法:每位入选患者均接受了针对非小细胞肺癌(≥60 Gy)的明确放射治疗,并生成了两个RTP数据集:单独使用CT和PET / CT得出的总肿瘤体积(GTV)。患者使用PET / CT衍生计划接受治疗。主要终点是PET / CT融合对治疗计划的影响,具体取决于每个患者的以下变量的差异:GTV,受累结节数,淋巴结站,平均肺部剂量(MLD),肺容量超过20 Gy (V20)和平均食道剂量(MED)。区域故障率是次要终点。非参数Wilcoxon配对配对带符号秩检验用于Bonferroni调整,总体显着性水平为0.05。结果:RTOG 0515共计52例患者,其中47例可评估。所有患者的随访时间均为12.9个月(2.7-22.2)。肿瘤分期如下:II = 6%; IIIA = 40%; IIIB = 54%。对于PET / CT衍生的体积,GTV在统计学上显着较小(98.7对86.2 mL; p <0.0001)。 PET / CT计划的MLD略低(19比17.8 Gy; p = 0.06)。涉及的结节数目(2.1 vs. 2.4),V20(32%vs. 30.8%)或MED(28.7 vs. 27.1 Gy)没有显着差异。 PET / CT改变了51%的患者的淋巴结轮廓。一名患者(2%)出现了选择性淋巴结衰竭。结论:PET / CT衍生的肿瘤体积小于单纯CT衍生的肿瘤体积。 PET / CT在51%的患者中改变了节点GTV轮廓。 PET / CT衍生的GTV的选择性结节失败率非常低,支持将目标体积限制在原发肿瘤和受累结节的RTOG标准。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号